Abstract
Many chronic inflammatory diseases are associated with deregulated intracellular signal transduction pathways. Resultant pathogenic interactions between immune and stromal cells lead to changes in cell activation, proliferation, migratory capacity, and cell survival that all contribute to inflammation. Increasing efforts are now being made in the design of novel therapeutic compounds to interfere with signaling pathways in inflammatory diseases like rheumatoid arthritis (RA). In this review we will outline the major signal transduction pathways involved in the pathogenesis of RA. We will assess advances in targeting a number of key intracellular pathways, including nuclear factor-κB (NF-κB), mitogen-associated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K) / Akt, signal transducers and activators of transcription (STATs), and reactive oxygen species (ROS) production. Finally, we will discuss recently identified lead molecules and the progress of selected compounds towards becoming new drugs for the treatment of inflammatory diseases.
Keywords: inflammatory disease, rheumatoid arthritis, signal transduction, nuclear factor, mitogen-activated protein kinase, reactive oxygen species, novel therapies
Current Pharmaceutical Design
Title: Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Volume: 11 Issue: 5
Author(s): Sander W. Tas, Philip H.J. Remans, Kris A. Reedquist and Paul P. Tak
Affiliation:
Keywords: inflammatory disease, rheumatoid arthritis, signal transduction, nuclear factor, mitogen-activated protein kinase, reactive oxygen species, novel therapies
Abstract: Many chronic inflammatory diseases are associated with deregulated intracellular signal transduction pathways. Resultant pathogenic interactions between immune and stromal cells lead to changes in cell activation, proliferation, migratory capacity, and cell survival that all contribute to inflammation. Increasing efforts are now being made in the design of novel therapeutic compounds to interfere with signaling pathways in inflammatory diseases like rheumatoid arthritis (RA). In this review we will outline the major signal transduction pathways involved in the pathogenesis of RA. We will assess advances in targeting a number of key intracellular pathways, including nuclear factor-κB (NF-κB), mitogen-associated protein kinases (MAPKs), phosphoinositide 3-kinase (PI3K) / Akt, signal transducers and activators of transcription (STATs), and reactive oxygen species (ROS) production. Finally, we will discuss recently identified lead molecules and the progress of selected compounds towards becoming new drugs for the treatment of inflammatory diseases.
Export Options
About this article
Cite this article as:
Tas W. Sander, Remans H.J. Philip, Reedquist A. Kris and Tak P. Paul, Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy, Current Pharmaceutical Design 2005; 11 (5) . https://dx.doi.org/10.2174/1381612053381918
DOI https://dx.doi.org/10.2174/1381612053381918 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carbohydrates in Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Interleukin-10 and Articular Cartilage: Experimental Therapeutical Approaches in Cartilage Disorders
Current Gene Therapy Activatable Molecular Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Using Microgravity for Defining Novel Anti-Atherosclerotic Therapy
Current Genomics Liver Fibrosis in Rheumatoid Arthritis Patients Treated with Methotrexate
Current Rheumatology Reviews The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Non-Steroidal Anti-Inflammatory Drugs Loaded Liposomes for Topical Treatment of Inflammatory and Degenerative Conditions
Current Medicinal Chemistry The Ca2+-Activated K+ Channel of Intermediate Conductance:A Molecular Target for Novel Treatments?
Current Drug Targets The Physiology, Pharmacology and Future of P2X7 as An Analgesic Drug Target: Hype or Promise?
Current Pharmaceutical Biotechnology A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma
Current Medicinal Chemistry Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Current Pharmaceutical Design Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy
Current Topics in Medicinal Chemistry Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets PET Measurements of cAMP-Mediated Phosphodiesterase-4 with (R)-[11C]Rolipram
Current Radiopharmaceuticals Curcumin: A Boon to Colonic Diseases
Current Drug Targets Autophagy Modulators and Neuroinflammation
Current Medicinal Chemistry Osmotically Regulated Flow of Flurbiprofen through In Situ Formed Asymmetric Membrane Capsule
Current Drug Delivery Computational Strategies for the Development of Novel Small Molecule Rheumatoid Arthritis Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Periodontal Diseases and Rheumatoid Arthritis: A Coincident Model for Therapeutic Intervention?
Current Drug Metabolism